Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 2/2013

01-06-2013 | Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Irreversible Electroporation: a Novel Option for Treatment of Hepatic Metastases

Author: Robert C. G. Martin II

Published in: Current Colorectal Cancer Reports | Issue 2/2013

Login to get access

Abstract

Irreversible electroporation (IRE) has shown promise for ablation of lesions in proximity to vital structures in the preclinical and now clinical setting. Studies of patients undergoing IRE for treatment of metastatic colorectal cancer to the liver were reviewed for patient and tumor characteristics, treatment-related complications, and local recurrence-free survival (LRFS) for ablated lesions. LRFS was calculated according to the Kaplan–Meier method, with secondary analyses stratified by procedural approach (laparotomy, laparoscopy, percutaneous) and tumor histological characteristics. Initial IRE success has been achieved in 95 % of treatments. The LRFS rates at 3, 6, and 12 months were 97.4 %, 94.6 %, and 59.5 %. There was a trend toward higher recurrence rates for tumors larger than 4 cm (hazard ratio 3.236, 95 % confidence interval 0.585-17.891; p = 0.178). IRE is a safe and effective treatment for metastatic colorectal cancer to the liver near vital structures. Continued evaluation is needed to determine optimal probe design and techniques.
Literature
1.
Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–24.PubMedCrossRef
2.
Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: a literature review. Int J Hepatol. 2011;2011:104685.PubMed
3.
Sindram D, Lau KN, Martinie JB, Iannitti DA. Hepatic tumor ablation. Surg Clin North Am. 2010;90:863–76.PubMedCrossRef
4.
Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999;210:655–61.PubMed
5.
Shiina S, Tagawa K, Unuma T, Takanashi R, Yoshiura K, Komatsu Y, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study. Cancer. 1991;68:1524–30.PubMedCrossRef
6.
Vogl TJ, Mack MG, Muller PK, Straub R, Engelmann K, Eichler K. Interventional MR: interstitial therapy. Eur Radiol. 1999;9:1479–87.PubMedCrossRef
7.
Christophi C, Muralidharan V. Treatment of hepatocellular carcinoma by percutaneous laser hyperthermia. J Gastroenterol Hepatol. 2001;16:548–52.PubMedCrossRef
8.
Vogl TJ, Eichler K, Straub R, Engelmann K, Zangos S, Woitaschek D, et al. Laser-induced thermotherapy of malignant liver tumors: general principals, equipment(s), procedure(s) – side effects, complications and results. Eur J Ultrasound. 2001;13:117–27.PubMedCrossRef
9.
Ravikumar TS, Steele Jr GD. Hepatic cryosurgery. Surg Clin North Am. 1989;69:433–40.PubMed
10.
Shen HP, Gong JP, Zuo GQ. Role of high-intensity focused ultrasound in treatment of hepatocellular carcinoma. Am Surg. 2011;77:1496–501.PubMed
11.
Shibata T, Niinobu T, Ogata N, Takami M. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer. 2000;89:276–84.PubMedCrossRef
12.
Yu NC, Lu DS, Raman SS, Dupuy DE, Simon CJ, Lassman C, et al. Hepatocellular carcinoma: microwave ablation with multiple straight and loop antenna clusters–pilot comparison with pathologic findings. Radiology. 2006;239:269–75.PubMedCrossRef
13.
• O'Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl. 2012;18:949–54. This is one of the largest studies to report on stereotactic (intensity-modulated) radiation therapy, similar to CyberKnife therapy in the case of hepatic tumors.PubMedCrossRef
14.
Lu MD, Xu HX, Xie XY, Yin XY, Chen JW, Kuang M, et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. J Gastroenterol. 2005;40:1054–60.PubMedCrossRef
15.
Komorizono Y, Oketani M, Sako K, Yamasaki N, Shibatou T, Maeda M, et al. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer. 2003;97:1253–62.PubMedCrossRef
16.
Kim SW, Rhim H, Park M, Kim H, Kim YS, Choi D, et al. Percutaneous radiofrequency ablation of hepatocellular carcinomas adjacent to the gallbladder with internally cooled electrodes: assessment of safety and therapeutic efficacy. Korean J Radiol. 2009;10:366–76.PubMedCrossRef
17.
Lim DH, Lee H, Park HC, Lee JA, Kim SW, Yoo BC, et al. The efficacy of high-dose 3-dimensional conformal radiation therapy in patients with small hepatocellular carcinoma not eligible for other local modalities. Am J Clin Oncol. 2012;1024:1024. doi:10.​1097/​COC.​0b013e3182438dae​.
18.
Krishnan S, Lin EH, Gunn GB, Chandra A, Beddar AS, Briere TM, et al. Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases. Am J Clin Oncol. 2006;29:562–7.PubMedCrossRef
19.
20.
• Bower M, Sherwood L, Li Y, Martin R. Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J Surg Oncol. 2011;104:22–8. This is the first report to demonstrate the safety of the use of IRE around vital blood vessels.PubMedCrossRef
21.
Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat. 2007;6:307–12.PubMed
22.
• Guo Y, Zhang Y, Klein R, Nijm GM, Sahakian AV, Omary RA, et al. Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma. Cancer Res. 2010;70:1555–63. This article is an additional report on the safety of IRE in the liver in an in vivo model.PubMedCrossRef
23.
Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the liver and liver hilum in swine. HPB. 2011;13:168–73.PubMed
24.
Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the pancreas in swine: a pilot study. HPB. 2010;12:348–51.PubMed
25.
Martin 2nd RC, McFarland K, Ellis S, Velanovich V. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg. 2012;215:361–9.PubMedCrossRef
26.
Martin 2nd RC, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol. 2012;2424:2424. doi:10.​1245/​s10434-012-2736-1.
27.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef
28.
Niessen C, Jung EM, Stroszczynski C, Wiggermann P. Ablation einer Lebermetastase mit irreversibler Elektroporation (IRE) im Lebersegment II angrenzend an die Area nuda [Ablation of a liver metastasis with irreversible electroporation (IRE) in liver segment II adjoining the area nuda]. Rofo. 2012;184:937–8.PubMedCrossRef
29.
• Cannon R, Ellis S, Hayes D, Narayanan G, Martin 2nd RC. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2012;2424:2424. doi:10.​1002/​jso.​23280. This is the largest study of the use of IRE for ablation of hepatic tumors close to vital structures with long-term 12-month follow-up.PubMed
30.
Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;22:611–21.PubMedCrossRef
Metadata
Title
Irreversible Electroporation: a Novel Option for Treatment of Hepatic Metastases
Author
Robert C. G. Martin II
Publication date
01-06-2013
Publisher
Current Science Inc.
Published in
Current Colorectal Cancer Reports / Issue 2/2013
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-013-0166-5

Other articles of this Issue 2/2013

Current Colorectal Cancer Reports 2/2013 Go to the issue

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

Colorectal Cancer in the Elderly: How Do We Tailor Treatment with Chemotherapy and Radiotherapy Most Appropriately?

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

The ALPPS Approach for the Management of Colorectal Carcinoma Liver Metastases

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Non-Size-Based Response Criteria to Preoperative Chemotherapy in Patients With Colorectal Liver Metastases: The Morphologic Response Criteria

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

How Could the TNM System Be Best Adapted for Staging Rectal Cancer in the Future?

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Use of Chemotherapy in the Resection of Liver Metastases of Colorectal Cancer

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

Is There a Role for Neoadjuvant Chemotherapy Without Radiotherapy in Locally Advanced Rectal Cancer?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits